About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CLVS - Clovis Oncology| Previous Close | $6.69 | Open | $6.77 |
| Volume | 3.37M | Market Cap | 581.62M |
| Yield | Last Dividend |
| Clovis Oncology to Highlight Rubraca?? (... | 06/17/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Highlight Rubraca?? (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annu... | |
| Why Is Clovis (CLVS) Down 17.2% Since La... | 06/04/20 |
| Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Clovis Oncology Announces New Recommenda... | 05/28/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network?? (NCC... | |
| Clovis Oncology Announces Presentations ... | 05/21/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program | |
| Clovis launches $85M stock offering on h... | 05/18/20 |
| Days after it landed approval to use its flagship drug to treat pancreatic cancer, Clovis Oncology Inc. said it intends to sell $85 million in new sto... | |
| Clovis Oncology Announces Pricing of Pub... | 05/18/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in... | |
| Clovis' (CLVS) Rubraca Gets FDA Approval... | 05/18/20 |
| Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate ca... | |
| Why Clovis Oncology's Stock Spiked Highe... | 05/15/20 |
| Clovis Oncology, Inc. (NASDAQ: CLVS ) shares traded higher on Friday afternoon after the company announced the FDA approved its Rubraca tablets for th... | |
| Rubraca?? (Rucaparib) Approved in the U.... | 05/15/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) appr... | |
| Is Clovis Oncology (CLVS) Stock a Solid ... | 05/14/20 |
| Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| 5 Top Stock Trades for Thursday: AAPL, S... | 05/13/20 |
| Apple, the S&P 500 ETF, Clovis Oncology, Spirit Airlines and Wells Fargo were our top stock trades to watch going into Thursday. | |
| Clovis (CLVS) Q1 Earnings and Revenues S... | 05/06/20 |
| Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up. | |
| Clovis Oncology Announces First Quarter ... | 05/05/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and pr... | |
| Clovis Oncology to Present at the Bank o... | 04/29/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patric... | |
| Are Options Traders Betting on a Big Mov... | 04/22/20 |
| Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately. | |
| Clovis Oncology Announces Debt Exchange ... | 04/14/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately neg... | |
| Clovis Oncology Analyst Turns Bearish Ah... | 04/09/20 |
| Despite optimistic expectations concerning label expansion for Clovis Oncology Inc's (NASDAQ: CLVS ) Rubraca to include prostate cancer, an analyst at... | |
| Clovis Oncology (CLVS) Gains As Market D... | 04/03/20 |
| Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session. | |
| Why Is Clovis (CLVS) Down 41.6% Since La... | 03/25/20 |
| Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Clovis (CLVS) Q4 Loss Wider Than Expecte... | 02/25/20 |
| Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down. | |
| Clovis Oncology (NASDAQ: CLVS): Q4 2019 ... | 02/24/20 |
| ??? Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. ??? Product reven... | |
| Clovis Oncology Announces 2019 Operating... | 02/24/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results | |
| Is Clovis Oncology (CLVS) Outperforming ... | 02/21/20 |
| Is (CLVS) Outperforming Other Medical Stocks This Year? | |
| Clovis Oncology to Announce Fourth Quart... | 02/13/20 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results ... | |
| 4 Stocks Looking Higher During Earnings ... | 02/06/20 |
| By Harry Boxer, TheTechTrader Here are three health stocks and one technology stock that are at or near key breakout points: Clovis Oncology, Inc. (NA... | |
| Clovis Oncology Is Poised For A Substant... | 02/04/20 |
| There's been acquisition rumors associated with this name, but we tend to disregard this rumor but rather, stay focused on what we believe to be an ad... | |
| Clovis Rubraca sNDA for Prostate Cancer ... | 01/16/20 |
| Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up. | |
| FDA Grants Priority Review Designation F... | 01/15/20 |
| Clovis Oncology Inc (NASDAQ: CLVS ) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug ... | |
| Clovis Oncology's stock soars after FDA ... | 01/15/20 |
| Shares of Clovis Oncology Inc. soared 22% in very active premarket trading Wednesday, after the biopharmaceutical company said the supplemental new dr... | |
| Initial Clinical Experience Reported fro... | 12/16/19 |
| BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initia... | |
| Buy rating | 05/22/20 |
| and lowers Price Target from $33.00 to $29.00 | |
| Underperform rating | 05/20/20 |
| SVB Leerink maintains Underperform rating and lowers Price Target from $5.00 to $4.00 | |
| Buy rating | 05/18/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $29.00 to $33.00 | |
| Buy rating | 05/06/20 |
| and raises Price Target from $27.00 to $29.00 | |
| Underperform rating | 04/27/20 |
| SVB Leerink downgrades from Market Perform to Underperform rating and announces Price Target of $5.00 | |
| Underperform rating | 04/09/20 |
| B of A Securities downgrades from Neutral to Underperform rating and announces Price Target of $6.00 | |
| Date | 2020-05-05 (BMO) | Est. (EPS/Rev.) | ($1.28)/ 41.24M |
| Actual (EPS/Rev.) | $-1.28/ $42.56 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| smashingdon | Paul | 63.00 % | Follow |
| Market Focus | Hao | 60.00 % | Subscribe |
| Best Trading Ideas | Best Trading Ideas | 53.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
